Ada Cockpit | March 2026
Key Finding: Daiichi Sankyo's oncology portfolio represents exceptional alignment with Ada Patient Finder's value proposition. The combination of significant diagnostic delays (breast cancer 73%, ovarian 31 weeks), high per-patient revenue ($80,000-$180,000 annually), and explicit company strategy focused on expanding patient pools creates a $4-7M annual opportunity at 5% penetration across Tier 1+2 approved drugs, scaling to $10-18M as pipeline drugs launch.
| Drug | Indication | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity (USA, 5% Penetration) |
|---|---|---|---|---|---|
| ENHERTU | HER2+ Breast Cancer | TIER 1 | 9/10 | 5,000-8,000 | $2.0-3.2M/year |
| R-DXd (Pipeline) | Platinum-Resistant Ovarian | TIER 1 | 8/10 | 2,000-4,000 | $0.9-1.8M/year |
| ENHERTU | HER2+ Gastric Cancer | TIER 2 | 7/10 | 1,000-1,500 | $400,000-600,000/year |
| VANFLYTA | FLT3-ITD+ AML | TIER 2 | 7/10 | 800-1,200 | $400,000-600,000/year |
| I-DXd (Pipeline) | Extensive-Stage SCLC | TIER 2 | 7/10 | 1,500-2,500 | $600,000-1.0M/year |
| Datroway | HR+/HER2- Breast Cancer | TIER 3 | 5/10 | 10,000-20,000 | $5.5-11M/year |
| HER3-DXd (Pipeline) | EGFR+ NSCLC | TIER 3 | 5/10 | 2,000-4,000 | $0.8-1.6M/year |
| INJECTAFER | Iron Deficiency Anemia | NO | 3/10 | Large but low revenue | <$5M |
| Lixiana/Savaysa | Atrial Fibrillation/VTE | NO | 2/10 | Minimal diagnostic delay | N/A |
| Nilemdo/Nustendi | Hypercholesterolemia | NO | 2/10 | Well-screened condition | N/A |
Symptoms: New breast lump, nipple discharge, skin changes (dimpling, peau d'orange), nipple retraction, breast pain, axillary lymph node enlargement. Metastatic: bone pain, shortness of breath, abdominal pain, neurological symptoms.
Diagnostic Delay: 73.5% exceed 52-day threshold; every additional month increases stage migration risk by 10%. Average mammography-to-biopsy: 19-21 days (USA), 8-29 days (Europe).
Common Misdiagnoses: Benign breast conditions, mastitis, hormonal changes. Critical issue: Young women (<40) excluded from screening; 40% report physicians dismissed concerns; 85% self-detected vs. clinical screening.
Ada can effectively identify breast cancer red flags through direct symptom capture (lump, nipple discharge, skin changes), pattern recognition (breast + constitutional symptoms), and risk factor integration (family history, age). HER2 status requires tissue testing; strategy is to surface all breast cancer suspects, then HER2 testing determines ENHERTU eligibility.
Extremely High. Earnings calls emphasize "new patient share" as primary KPI. 100,000+ eligible patient opportunity cited as key to 2030 growth targets. CEO Okuzawa's "Global Top 10 Oncology by 2030" vision requires patient acquisition at scale. AstraZeneca partnership economics incentivize volume.
| Penetration | Patients Found | Annual Ada Revenue |
|---|---|---|
| 1% | 50-80 | $400,000-$640,000 |
| 5% | 250-400 | $2.0-3.2M |
| 10% | 500-800 | $4.0-6.4M |
Pipeline drug - Phase 3 REJOICE-Ovarian01 ongoing; Breakthrough Therapy Designation September 2025
Symptoms (The "Big Four"): Persistent bloating (>3 weeks), pelvic/abdominal pain, difficulty eating/early satiety, urinary symptoms (frequency, urgency). Also: back pain, fatigue, menstrual irregularities.
Diagnostic Delay: 31 weeks average globally. 30% initially misdiagnosed as IBS, menopause, GERD. Result: >75% diagnosed at advanced stage.
Common Misdiagnoses: IBS (30%), menopause symptoms, GERD/dyspepsia, UTI, fibroids.
Ada can identify the "Big Four" symptom constellation and differentiate persistent/progressive ovarian cancer symptoms from cyclical IBS patterns. Pattern: bloating + pelvic pain + urinary symptoms + eating difficulty, persistent >3 weeks, non-cyclical. Challenge: Symptoms highly non-specific; requires careful algorithm tuning to balance sensitivity/specificity.
Very High. Pipeline drug needs patient finding strategy pre-launch. $22B Merck partnership success depends on R-DXd uptake. Breakthrough Designation signals regulatory urgency. Pre-launch patient identification can support Phase 3 enrollment and launch readiness.
| Penetration | Patients Found | Annual Ada Revenue |
|---|---|---|
| 1% | 20-40 | $180,000-$360,000 |
| 5% | 100-200 | $0.9-1.8M |
| 10% | 200-400 | $1.8-3.6M |
Key Stats: 5,520 HER2+ gastric cases/year (20% of 27,600 total); 4.2-7.75 month diagnostic delay; 30% misdiagnosed as IBS/GERD/ulcers; >75% diagnosed at advanced stage.
Ada Capability: 7/10 - Can identify alarm symptoms (weight loss, dysphagia, GI bleeding, persistent dyspepsia >2 weeks). Overlap with benign GI conditions requires differentiation.
Key Stats: 5,226 FLT3-ITD+ AML cases/year (23% of 22,720 total AML); symptoms mimic flu-like illness; QuANTUM-First trial showed 22% reduction in death risk (median OS 32mo vs. 15mo).
Ada Capability: 6/10 - Can identify concerning constellation (fatigue + fever + bruising + infections); very non-specific but combination + duration flags urgent CBC need.
Key Stats: 20,720 ES-SCLC cases/year (56% of ~37,000 total SCLC); 86% diagnosed at extensive stage; Lambert-Eaton syndrome missed in >90%; Phase 2 ORR 54.8%; Breakthrough Designation.
Ada Capability: 6/10 - Respiratory symptoms in smokers + unique LEMS pattern (proximal muscle weakness). Overlap with COPD challenges diagnosis.
Rationale for Tier 3: Largest addressable delayed population (70% of breast cancers) with highest PF fee ($11,000), BUT HR+/HER2- is slower-growing, less aggressive than HER2+ or TNBC. Prioritizing common subtype (better screening outcomes) over rare/aggressive diseases with worse delays is lower strategic impact. Include in portfolio but not lead asset.
Status: BLA withdrawn May 2025 (manufacturing issues + OS miss). Development ongoing but major setback; unclear timeline for re-filing. Part of Merck $22B partnership so not abandoned.
| Drug | Indication | Fit Score | Rationale |
|---|---|---|---|
| INJECTAFER | Iron Deficiency Anemia | 3/10 | Low per-patient revenue (~$8,600 per course); PF fee only $860 despite large undiagnosed population; does not meet $10K/year threshold |
| Lixiana/Savaysa | Atrial Fibrillation/VTE | 2/10 | Minimal diagnostic delay (AFib well-detected via ECG); patent expiry 2027-2028; generic competition imminent; commodity NOAC market |
| Nilemdo/Nustendi | Hypercholesterolemia | 2/10 | Well-screened condition (routine cholesterol testing); primary prevention (proactive, not reactive); no diagnostic delay issue |
Dominant market position (>50% new patient share), explicit company focus on expanding eligible patient pool to 100,000+ by 2026. Proven Ada capability to surface breast cancer (9/10) and gastric cancer (7/10) symptoms. Immediate revenue opportunity: $2.4-3.8M/year @ 5% penetration.
R-DXd (ovarian): BLA expected 2026-2027; Breakthrough Designation. I-DXd (SCLC): Phase 3 ongoing; Breakthrough Designation. Pre-launch patient identification supports Phase 3 enrollment, launch readiness, and immediate post-approval capture.
Daiichi Sankyo's 2030 vision ("Global Top 10 Oncology Company") requires patient acquisition at scale. AstraZeneca partnership (ENHERTU, Datroway) creates co-selling dynamics. Merck partnership ($22B, 3 ADCs) extends opportunity beyond Daiichi alone.
Largest addressable delayed population (10,000-20,000 USA) with highest per-patient PF fee ($11,000). Potential $5.5-11M annually @ 5% penetration. Trade-off: Common subtype (HR+/HER2-) vs. rare/aggressive diseases with worse delays. Recommendation: Include in portfolio but not lead asset.
Daiichi Sankyo's oncology portfolio represents exceptional alignment with Ada Patient Finder's value proposition. The combination of:
...creates a $4-7M annual opportunity (Tier 1+2 approved drugs, 5% penetration) with potential to scale to $10-18M as pipeline drugs launch and penetration increases.
Recommended Approach: Lead with ENHERTU (breast + gastric), position for R-DXd/I-DXd pipeline launches, and leverage Daiichi Sankyo's 2030 vision as the strategic alignment anchor. The company's explicit focus on "new patient share" as the primary KPI, combined with CEO Okuzawa's goal to become a "Global Top 10 Oncology Company by 2030," creates ideal partnership conditions for Ada Patient Finder.